Better Outcome of Off-Label High-Dose Ceftazidime in Hemato-Oncological Patients with Infections Caused by Extensively Drug-Resistant Pseudomonas Aeruginosa

BACKGROUND: P. aeruginosa sepsis in immunocompromised patients is a serious complication of cancer treatment, especially in the case of an Extensively Drug Resistant (XDR) pathogen. The aim of the study is to evaluate the efficacy of high-dose ceftazidime in the treatment of XDR P. aeruginosa infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavrelova, Alzbeta, Paterova, Pavla, Zak, Pavel, Visek, Benjamin, Sima, Martin, Radocha, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833305/
https://www.ncbi.nlm.nih.gov/pubmed/36660352
http://dx.doi.org/10.4084/MJHID.2023.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833305/
https://www.ncbi.nlm.nih.gov/pubmed/36660352
http://dx.doi.org/10.4084/MJHID.2023.001

Ejemplares similares